picankibart vs SHR-1139

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: IL-23 p19 · full Psoriasis pipeline

picankibart

Marketed by Innovent Biologics

Phase 3 in Psoriasismonoclonal antibody (anti-IL-23p19)
Reliable signal

NCT05645627 · Phase 3 · completed

CLEAR-1 was a randomized, double-blind, placebo-controlled Phase 3 trial in 500 Chinese adults with moderate to severe plaque psoriasis. Patients received picankibart 200 mg or placebo for the first 16 weeks. The two primary endpoints at week 16 were at least 90% improvement in PASI and a clear or almost clear sPGA score. With picankibart, 80.3% reached PASI 90 and 93.5% reached sPGA 0/1, against 2.0% and 13.1% with placebo (p<0.0001 for both), so the trial met both primary endpoints. The response rates come from the peer-reviewed paper in the Journal of the American Academy of Dermatology and the p-values from the company announcement.

Reported efficacy

Percentage of participants with a Psoriasis Area and Severity Index (PASI) 90 Response (Week 56): PASI 90 maintenance at Week 56: 89.3% (100 mg) and 90.1% (200 mg) picankibart-maintenance groups vs 37.7% and 51.7% in the corresponding randomized-withdrawal groups; P < 0.0001 for both comparisons (met)

Result source: NCT06049810

SHR-1139

Developed by Jiangsu Hengrui Pharmaceuticals

Phase 2 in Psoriasismonoclonal antibody (dual IL-23p19/IL-36R)
Weak signal

NCT07051538 · Phase 1 · completed

This early-phase study randomized 64 participants to SHR-1139 or placebo under full blinding, but it was designed to check safety and tolerability, not to test whether the drug improves psoriasis, and no results have been posted, so no conclusion about benefit can yet be drawn from it. Its registered primary outcome on ClinicalTrials.gov is "Adverse events (AEs)" (with 3 other safety or dose-finding measures). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: December 2026 · NCT07719530 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointpicankibartSHR-1139
PASI 75—Not posted · NCT05645627—Not reported
PASI 9080.3% vs 2%a+78.3 vs placebowk 16NCT05645627—Not reported
PASI 100—Not posted · NCT05645627—Not reported
sPGA 0/1—Not posted · NCT05645627—Not reported
DLQI, change—Not posted · NCT05645627—Not reported

PASI 75

picankibart
—Not posted · NCT05645627
SHR-1139
—Not reported

PASI 90

picankibart
80.3% vs 2%a+78.3 vs placebowk 16NCT05645627
SHR-1139
—Not reported

PASI 100

picankibart
—Not posted · NCT05645627
SHR-1139
—Not reported

sPGA 0/1

picankibart
—Not posted · NCT05645627
SHR-1139
—Not reported

DLQI, change

picankibart
—Not posted · NCT05645627
SHR-1139
—Not reported
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

SHR-1139: no structured comparison results are available for Psoriasis.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

picankibart

PASI 90 80.3% vs 2% placebo @ 16wk
responder rate · % of participants
NCT05645627 · Phase 3 · sponsor-reported, not registry data
PASI 90 Response Maintenance 90.1% vs 51.7% corresponding randomized-withdrawal group @ 56wk200 mg picankibart-maintenance
responder rate · % of participants
NCT06049810 · Phase 3 · sponsor-reported, not registry data
show 1 more result
89.3% vs 37.7% corresponding randomized-withdrawal group @ 56wk100 mg picankibart-maintenance
NCT06049810 · Phase 3 · sponsor-reported, not registry data

Ulcerative Colitis

Shared mechanism: IL-23 p19 · full Ulcerative Colitis pipeline

picankibart

Marketed by Innovent Biologics

Phase 2 in Ulcerative Colitismonoclonal antibody (anti-IL-23p19)
Partial signal

NCT05377580 · Phase 2 · completed

This randomized, quadruple-blind, placebo-controlled Phase 2 trial enrolled 150 patients with moderately to severely active ulcerative colitis and tested several doses of picankibart against placebo. The primary endpoint was clinical remission at Week 12. The sponsor reported remission in 20.0% of patients on 200 mg and 14.0% on 600 mg versus 2.0% on placebo (p<0.05), so the primary endpoint was met; no power calculation or planned enrolment was found in the sources checked.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Reported efficacy

Evaluate the effectiveness of IBI112 in inducing clinical remission in patients with moderately to severely active ulcerative colitis (UC) (week 12): Week 12 clinical remission (primary endpoint): picankibart 200 mg 20.0% and 600 mg 14.0% vs placebo 2.0% (p<0.05). (met)

Result source: NCT05377580

SHR-1139

Developed by Jiangsu Hengrui Pharmaceuticals

Phase 2 in Ulcerative Colitismonoclonal antibody (dual IL-23p19/IL-36R)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: August 2027 · NCT07232576 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointpicankibartSHR-1139
Clinical remission (induction)—Not reported—Not reported
Clinical remission (maintenance)—Not reported—Not reported
Clinical response (induction)—Not reported—Not reported
Endoscopic improvement (induction)—Not reported—Not reported
Corticosteroid-free remission (maintenance)—Not reported—Not reported

Clinical remission (induction)

picankibart
—Not reported
SHR-1139
—Not reported

Clinical remission (maintenance)

picankibart
—Not reported
SHR-1139
—Not reported

Clinical response (induction)

picankibart
—Not reported
SHR-1139
—Not reported

Endoscopic improvement (induction)

picankibart
—Not reported
SHR-1139
—Not reported

Corticosteroid-free remission (maintenance)

picankibart
—Not reported
SHR-1139
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

SHR-1139: no structured comparison results are available for Ulcerative Colitis.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

picankibart
Week 12 clinical remission (primary endpoint): picankibart 200 mg 20.0% and 600 mg 14.0% vs placebo 2.0% (p<0.05). NCT05377580 · Phase 2 · design grade: moderate · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: picankibart's landscape · SHR-1139's landscape